🇺🇸 FDA
Patent

US 8178671

Methods of treating or preventing autoimmune diseases with 2, 4-pyrimidinediamine compounds

granted A61KA61K31/506A61K31/538

Quick answer

US patent 8178671 (Methods of treating or preventing autoimmune diseases with 2, 4-pyrimidinediamine compounds) held by Rigel Pharmaceuticals, Inc. expires Mon May 10 2032 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
Rigel Pharmaceuticals, Inc.
Grant date
Tue May 15 2012 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon May 10 2032 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
10
CPC classes
A61K, A61K31/506, A61K31/538, A61K31/541, A61P